Co-infection of Cytomegalovirus and Epstein-Barr Virus Diminishes the Frequency of CD56
Age Factors
Cell Degranulation
/ immunology
Cell Line
Child, Preschool
Coinfection
Cytomegalovirus
/ immunology
Cytomegalovirus Infections
/ complications
Disease Susceptibility
Epstein-Barr Virus Infections
/ complications
Female
Herpesvirus 4, Human
/ immunology
Humans
Immunocompromised Host
Immunophenotyping
Immunosuppression Therapy
Immunosuppressive Agents
/ administration & dosage
Infant
Killer Cells, Natural
/ immunology
Lymphocyte Activation
/ genetics
Lymphocyte Count
Lymphocyte Subsets
/ immunology
Lymphoproliferative Disorders
/ etiology
Male
Organ Transplantation
/ adverse effects
Receptors, KIR
/ metabolism
Time Factors
Viral Load
EBV
KIR
NKG2A
cytomegalovirus
immunosuppression
infectious mononucleosis
natural killer cells
post-transplant lymphoproliferative disorder
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
17
02
2020
accepted:
15
05
2020
entrez:
7
7
2020
pubmed:
7
7
2020
medline:
13
4
2021
Statut:
epublish
Résumé
Post-transplant lymphoproliferative disorder (PTLD) is a rare but potentially life-threatening complication, frequently associated with Epstein-Barr virus (EBV), which develops after solid organ or stem cell transplantation. Immunosuppression received by transplant recipients has a significant impact on the development of PTLD by suppressing the function of T cells. The preferential proliferation of NKG2A-positive natural killer (NK) cells during primary symptomatic EBV infection known as infectious mononucleosis (IM) and their reactivity toward EBV-infected B cells point to a role of NK cell in the immune control of EBV. However, NK cell-mediated immune response to EBV in immunosuppressed transplant recipients who develop PTLD remains unclear. In this study, we longitudinally analyzed the phenotype and function of different NK cell subsets in a cohort of pediatric liver transplant patients who develop PTLD and compared them to those of children with IM. We found persistently elevated plasma EBV DNA levels in the PTLD patients indicating suboptimal anti-viral immune control. PTLD patients had markedly decreased frequency of CD56
Identifiants
pubmed: 32625211
doi: 10.3389/fimmu.2020.01231
pmc: PMC7311655
doi:
Substances chimiques
Immunosuppressive Agents
0
Receptors, KIR
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1231Informations de copyright
Copyright © 2020 Lam, Azzi, Hui, Wong, McHugh, Caduff, Chan, Münz and Chiang.
Références
Transpl Int. 2016 Nov;29(11):1226-1236
pubmed: 27564782
Pediatr Transplant. 2009 May;13(3):319-23
pubmed: 18397216
Transplantation. 2017 Sep;101(9):2009-2016
pubmed: 28376031
Front Immunol. 2016 Dec 15;7:607
pubmed: 28018364
PLoS One. 2013;8(4):e60784
pubmed: 23573283
Pediatr Transplant. 2013 Dec;17(8):806-14
pubmed: 24118875
Front Oncol. 2018 Jun 13;8:211
pubmed: 29951372
Crit Rev Oncol Hematol. 2005 Oct;56(1):155-67
pubmed: 15979320
Cell Rep. 2013 Dec 26;5(6):1489-98
pubmed: 24360958
Blood. 2010 Nov 11;116(19):3865-74
pubmed: 20733159
J Exp Med. 1998 Mar 2;187(5):813-8
pubmed: 9480992
Front Oncol. 2019 Feb 12;9:62
pubmed: 30809508
Blood. 2010 Sep 30;116(13):2245-52
pubmed: 20562330
J Immunol. 2002 Apr 15;168(8):4184-91
pubmed: 11937579
Trends Immunol. 2014 Apr;35(4):159-69
pubmed: 24589417
Exp Mol Med. 2015 Jan 23;47:e132
pubmed: 25613729
Front Microbiol. 2018 Mar 07;9:416
pubmed: 29599759
Am J Transplant. 2005 Sep;5(9):2222-8
pubmed: 16095501
Immunology. 2011 Oct;134(2):161-71
pubmed: 21896011
PLoS Pathog. 2020 Apr 6;16(4):e1008477
pubmed: 32251475
Ann Surg. 2002 Oct;236(4):429-36; discussion 436-7
pubmed: 12368671
Am J Hum Genet. 2006 Apr;78(4):721-7
pubmed: 16532402
Trends Immunol. 2001 Nov;22(11):633-40
pubmed: 11698225
Am J Transplant. 2013 Mar;13(3):656-62
pubmed: 23331474
J Leukoc Biol. 2010 Dec;88(6):1089-97
pubmed: 20671192
J Infect Dis. 2010 Aug 15;202(3):461-9
pubmed: 20560768
J Infect Dis. 1997 Dec;176(6):1462-7
pubmed: 9395355
Eur J Immunol. 1997 Feb;27(2):563-7
pubmed: 9045931
PLoS Pathog. 2019 May 30;15(5):e1007748
pubmed: 31145756
Transpl Infect Dis. 2009 Oct;11(5):393-9
pubmed: 19497070
Proc Natl Acad Sci U S A. 2011 Sep 6;108(36):14725-32
pubmed: 21825173
Blood. 2019 Mar 28;133(13):1479-1488
pubmed: 30647027
Sci Immunol. 2016 Sep;1(3):
pubmed: 27868107
Nature. 2009 Jan 29;457(7229):557-61
pubmed: 19136945
Blood. 2014 Oct 16;124(16):2533-43
pubmed: 25205117
Eur J Immunol. 2012 Feb;42(2):541-50
pubmed: 22105417
Nat Med. 1996 Aug;2(8):906-11
pubmed: 8705861
Transplantation. 1996 Aug 15;62(3):370-5
pubmed: 8779685
J Clin Invest. 2012 Mar;122(3):821-32
pubmed: 22354167
Transplantation. 2003 Apr 15;75(7):987-93
pubmed: 12698085
Trends Immunol. 2018 Mar;39(3):222-239
pubmed: 29397297
Am J Transplant. 2008 May;8(5):1016-24
pubmed: 18312608
J Immunol. 2014 Jan 1;192(1):503-11
pubmed: 24307732